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Abstract
Background: In ascertained allergic sensitization to Vespa crabro (VC) venom, the European guidelines still consider
venom immunotherapy (VIT) with Vespula (VE) venom sufficient to achieve an adequate protection against VC. However,
antigen 5 immunoblotting studies showed that a genuine sensitization to VC venom may exist. In such cases, a specific
VC venom would be preferable for VIT treatment. Since in the last few years, VC venom extracts became available for
diagnosis and desensitization, we assessed the efficacy and safety of VIT with a VC-VIT, compared to VE extract.
Methods: Patients stung by VC, and carefully diagnosed for specific sensitization and indication to VIT underwent a 5-
year course of immunotherapy with either VE or VC extracts. The severity of reactions at the first sting (pre-VIT) and after
field re-stings (during VIT) were compared.
Results: Eighty-three patients, treated with VE extract and 130 patients treated with VC extract completed the 5-year
course of VIT. Only a fraction of those patients (43,8%) were field-re-stung by VC: 64 patients on VC VIT and 69 on VE VIT.
In the VC VIT group, reactions at re-sting were: 50 negative, 12 large local reactions, 4 systemic reactions (Muller grade I).
In this group the VC VIT efficacy was 93,8%. In the VE VIT treated group the reactions at VC re-sting were: 51 negative, 10
large local reactions and 9 systemic reactions (5 Muller I, 3 Mueller III, 1 Muller IV). In this group the overall efficacy of VIT
was 87,0%. The difference in efficacy between the two groups was not statistically significant, as previously reported in
literature. Nonetheless, field sting systemic reactions Muller III and IV were recorded only in those patients receiving VE
VIT.
Conclusion: This observation suggests that in patients with ascertained VC-induced allergic reactions a specific VC VIT,
where available, would be more adequate, at least concerning the safety profile.
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Background
Despite relatively rare, Hymenoptera venom allergy
(HVA) remains an important cause of severe reactions
and even fatalities. The occurrence of insect sting-
related mortality ranges between 0.03 and 0.48 fatalities
per 1,000,000 individuals per year [1]. The main respon-
sible of those events are the insects belonging to the
families of Vespidae (including Vespinae and Polistinae),
being Vespula and Dolichovespula the most frequent al-
lergenic sources. Within the genus Vespula (VE) there
are Vespula germanica and Vespula vulgaris, which are
usually smaller in dimensions, and differ from Dolichove-
spula in some other morphological aspects for instance,
Dolichovespula has a sagittaly more elonged head. In
Europe, the most represented species are Dolichovespula
media, D. saxonica and D. sylvestris. Within the genus
Vespa, Vespa crabro (VC) (European hornet) is
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predominant [2]. Of note, also Polistes spp. are currently
recognized as a relevant allergenic source [3].
The molecular composition of the venoms of the most
represented species is known quite in detail. The most
important vespid allergens are phospholipase A1, hyal-
uronidase, and antigen 5 (Ag-5). These antigens are
present both in VE and in VC venoms [4]. Among ves-
pids, venoms are usually widely cross-reactive. In fact,
most of the VE allergens share a 95% homology [5, 6] in
their aminoacid sequency. As a consequence, also diag-
nostic and therapeutic extracts may display a certain
cross-reactivity [7, 8]. Also, there is a not negligible
cross-reactivity among Vespula, Vespa and Dolichove-
spula venoms [9, 10].
Studies conducted in the Mediterranean area showed
that the risk of developing severe systemic reactions is
increased by about three-fold with VC, as compared to
honeybee or VE species [11]. It can be hypothesized that
some of the patients with HVA due to VC were previ-
ously sensitized by VE stings. Thus, in those subjects
with an ascertained VC systemic reactions, the venom
immunotherapy (VIT) with VE extracts would be suffi-
cient to confer protection, and this is what the European
guidelines suggest [12–14]. On the other hand, CAP-
inhibition and immunoblotting-based studies showed
that those techniques remained inconclusive in about
50% patients, suggesting that sensitization against VC
Ag-5 is relevant and genuine [11]. The phylogenetic tree,
concerning Ag-5, confirms that VE and VC are quite
distant [15, 16].
Since a commercial extract for diagnosis and VIT for
VC is now available in Italy (and can be used everywhere
as named-patient product), we compared the efficacy
and safety of VC and VE VIT in patients with ascer-
tained reactions to VC. This was done directly evaluat-
ing the field re-stings during VIT.
Methods
All the involved patients were recruited at various Al-
lergy Centres in Italy (Como, Faenza, Firenze and Rim-
ini) and received VIT according to the EAACI guidelines
[11] and standard of care. Most patients, obviously, re-
ceived VE VIT, since VC preparations were not available
before 1990. Consecutive patients referred to our units
for a previous systemic reaction following a VC sting
(from to 1990 to 2016) were observed. Only patients
who could recognize or document with certainty VC as
the stinging hymenoptera were included. Systemic reac-
tions were graded according to Mueller [17]. The diag-
nostic procedures were those recommended by the
European Academy of Allergy and Clinical Immunology
[11, 18]. These procedures included skin prick test,
intradermal test and CAP-assay for honeybee, Vespula
spp. (Alk, Hornsholm, Denmark; Stallergenes, Antony
Cedex, France), Polistes dominula and Vespa crabro
(Anallergo, Florence, Italy). In parallel, specific IgE by
ImmunoCAP-assay (Phadia AB, Upssala, Sweden) for
the mentioned allergenic sources and serum tryptase by
ImmunoCAP (Phadia AB, Upssala, Sweden) were carried
out. According to the results of diagnostic tests, clinical
indications, judgement of physicians, and availability of
the VC extract the patients were allocated to either VE
VIT (Alk, Hornsholm, Denmark; Stallergenes, Antony
Cedex, France) or VC (Vespa Crabro, Anallergo,
Florence, Italy) VIT. A modified rush protocol was used
in both the VC and VE groups. For VE VIT, an aqueous
extract (100 mcg/mL) was used during build-up and
maintenance. For VC VIT, an aqueous extract (100 mcg/
mL) was used in the first two sessions, then a tyrosine-
absorbed extract was given at maintenance (Table 1).
During the first 3 sessions the escalating doses were
given at 30-min intervals, until the 4th session, when the
maintenance dose of 100 mcg/mL was administered. At
maintenance, a 100 mcg/mL dose was given monthly for
the first year, then every 6 or 8 weeks until the 5th year.
On field re-sting reactions (number and severity) by VC
were assessed and described in the two groups. If there
was more than one re-sting without reactions in the
same patient, only the first re-sting was counted and
recorded.
The dataset was aggregated by patient, and summary
statistics for key variables were calculated for each single
patient at the beginning and end of the immunotherapy
(0 and 60 months). To compare the efficacy between the
two therapies in reducing the reaction to subsequent
stings, we considered only patients who completed the
course of VIT (60 months) and were field re-stung by
VC within this time frame. We also compared the most
severe reactions at re-sting versus those reported at the
initial diagnosis, and the most severe reactions to sting
reported during the 5 years of the VIT course. Moreover,
we compared the results from the IgE specific
Table 1 Build-up phase for rush VIT
Day Concentration mcg/ml Dose in mcg
1 0.1 0.01
1 0.1
1 1
10 3
2 10 5
100 10
100 20
3 100 30
100 35
100 35
10 100 100
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immunoassay and the skin test (in logarithmic scale) at
time 0 and at the end of the therapy (after 60 months)
using a General Linear Model (GLM) analysis for re-
peated measures. Sex ratio, age, specific IgE values, skin
test results and worst reaction reported at baseline were
compared between the two groups (VE vs VC) to assess
the homogeneity of datasets at the beginning of VIT.
Sex ratio, intradermal results to VC and systemic reac-
tions by VC at baseline were compared using a Pearson
chi-square analysis, whereas the other values were com-
pared using the Student’s t test or Mann-Whitney tests
for independent samples in the case of not homoge-
neous variance at the Welch’ test for variance homogen-
eity [19]. For all post-treatment univariate tests, we
report both the one- and two-tails test, under the
assumption that VC VIT could be more effective. The
probability distributions for the Mann-Withney tests, as
well as for the Chi-Square tests were estimated using a
permutation (Exact) approach [20]. All statistical
analyses were carried out using IBM® SPSS® Statistics
Ver. 24.
Results
Systemic reactions were graded according to Mueller
[18]. In total, 303 patients (229 male, age range 10–78)
(Table 2) with a systemic reaction due to ascertained VC
sting were included. Of them, 83 received VE VIT and
220 VC VIT. There was no significant difference be-
tween the two groups at baseline, but for age and
threshold intradermal reactivity to VC (Table 2).
Among the considered population of 303 patients, 133
(43.8%) were re-stung by VC during the 5-year VIT
course: 64 on VC VIT and 69 on VE VIT. The VE group
patients totalized 99 on-field re-stings. We compared
the worst reaction at baseline (before VIT), and the
worst reaction at re-sting during VIT. In this group, dur-
ing VIT there were: 51 no reaction, 10 large local reac-
tions and 9 systemic reactions (5 grade Mueller I, 3
grade III, 1 grade IV) (Table 3). The VC group patients
had a total of 98 re-stings: 48 no reaction, 12 large local
reactions and 4 systemic reactions (all grade Mueller I)
(Table 3). Of note, 93.8% (60/64) of patients treated with
VC venom and 87.0% (60/69) of those treated with VE
venom, were protected at re-sting. This difference was
not statistically significant (X2 = 1.738, df = 1, P Exact(2-
tails) = 0.247, Exact(1-tail) = 0.153).
When these relations where examined by the GLM ap-
proach, we detected an overall significant effect of im-
munotherapy (within subjects effect for VIT; F =
952.446, df = 1, P ≤ 0.001) with a significant reduction in
the severity of the response to VC sting during VIT. On
the other hand no significant effect between the different
venoms (between subjects; F1, 118 = 0.043, P = 0.837), to
the baseline values of intradermal reactivity to VC
(between subjects; F1, 118 = 0.985, P = 0.323) or to spe-
cific IgE to VC (between subjects; F1, 118 = 0.979, P =
0.325), even when controlling for possible within sub-
jects second-term interactions (all VIT interaction terms
P ≥ 0.05).
No patient treated with VC venom had systemic reac-
tions more severe than Mueller I, whereas in the VE
Table 2 Characteristics of the population of patients receiving VE or VC VIT between 1990 and 2016. Mean, minimum and
maximum values are reported along with the levels of significance for the Student’s (t), Mann-Whitney (MW) and chi-square (X2)
tests. The significant differences are in bold
Group VC N = 220 Group VE N = 83 Statistical differences
Age mean (range) 49.9 (10–78) 43.7 (15–74) MW, P < 0.014
M/F 166/54 66/17 X2, P = 0.544
Grade before VIT n (%) X2, PExact = 0.134
Mueller 1 13 (6%) 0 (0%)
Mueller 2 30 (14%) 11 (14%)
Mueller 3 64 (29%) 29 (34%)
Mueller 4 111 (51%) 43 (52%)
VC Intradermal test (thereshold in mcg/ml)a X2, P = 0.003
1 mcg/ml 45 (20%) 26 (31%)
0,1 mcg/ml 70 (32%) 34 (41%)
0,01 mcg/ml 60 (27%) 20 (24%)
0,001 mcg/ml 21 (10%) 3 (4%)
0,0001 mcg/ml 24 (11%)
VC specific IgE mean (range) kU/L 2.1 (0.3–73.8) 3.0 (0.2–32.9) t, P > 0.05
Tryptase, mean (range) 5.5 (1–40) 5.2 (1.3–39.1) t, P > 0.05
alowest venom concentration able to induce at least a 5-mm diameter’s wheal with erythema
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group 5.8% (4/69) had Mueller III or IV reactions
(Table 3). In this case, we detected an almost significant
difference comparing the number of severe reactions out
of the total number of reactions in the two groups (VE
= 4/9, VC, 0/4; X2 = 2.568, df = 1, PExact(2-tails) = 0.120, P1-
tail = 0.069), particularly assuming a 1-tail test, given the
expectation is that the VC vaccine is more effective than
the VE one. Similarly, when comparing mild reactions
(large local +Mueller 1) and severe reactions (Mueller
2–4) in the two groups an almost significant trend was
seen (VE, 15/4; VC, 16/0; X2 = 3.803, df = 1, P Exact(2-tails)
= 0.109, P Exact(1-tail) = 0.074) clearly due to the small
sample size.
There was no severe adverse event due to VIT treat-
ments: only LLRs occurred during the build-up phase,
not interfering with the administration schedule. Finally,
the safety of the VC VIT was confirmed as safe as for
other preparations [10, 14].
Discussion
VC stings are frequently at risk for severe or life-
threatening reactions in sensitized subjects [10]. Usually,
in patients with ascertained systemic reactions from VC,
VIT with VE extracts is considered effective and safe.
Nonetheless, some patients may have a sensitization to
epitopes of VC allergens [21] that are not covered by the
standard VE extracts, as shown by mass spectrometry
analyses [22]. As a matter of fact, in a previous study in-
volving 202 patients with VC sting and treated with VE
VIT [13], the use of VE VIT was justified by the fact that
the majority of patients would be not have previously
been sensitized by VE stings. In this study, after field
resting, out of 8 stings 5 were negative, one had a large
local, and two systemic reactions.
The present study, by assessing in prospective way the
characteristics of field re-stings, showed that both VE
and VC VIT are equally effective, thus overall confirm-
ing the data reported in literature so far. Nonetheless,
reactions Mueller III and Muller IV grade at field re-
sting were observed only in patients treated with VE-
VIT; this suggests the hypothesis that in patients with
VC sting systemic reactions, a VC-VIT might be more
adequate. The difference was not formally significant,
but this can be ascribed to the small number of patients
who actually had severe reactions (n = 13). It is true that
the study was not randomized, but populations were
homogeneous, and the same diagnostic procedures were
used in all patients. In addition this model is quite
“clean” since VC can be easily distinguished from other
species, due to the dimensions and the essentially noc-
turnal habits. A gap still exists in the diagnostic ap-
proach since, at present, recombinant molecules for
diagnosis are available for Ag-5 of VE and polistes, but
not for VC, which partly differ from the other species
[14, 23]. So far, the literature about VC allergy remains
poor [23]. Probably, the introduction of diagnostic prep-
aration more specific for the various species will further
refine the prescription of VIT.
Conclusion
In conclusion, our results suggest that in patients with
ascertained VC systemic reactions, a VC-specific VIT,
where available, might be more adequate at least from
the safety viewpoint. Where VC VIT is not commercially
available, the VE VIT can be used, with a comparable ef-
ficacy. In addition, the safety of the VC VIT preparation
herein described is comparable to that of the VE prepa-
rations, during the rush build-up phase. Of course, fu-
ture studies including larger samples are required.
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Table 3 Outcome of field re-sting in 133 patients during the 5-
year VE or VC VIT. Response severity before and during VIT are
reported as absolute numbers
VE VIT (n = 69) VC VIT (n = 64)
Before During Before During
NEG 0 50 0 48
LLR 0 10 0 12
Muller 1 0 5 3 4
Muller 2 9 0 7 0
Muller 3 25 3 21 0
Muller 4 35 1 33 0
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